Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial

Randomized Controlled Trial

Wijnand Laan et al. J Clin Psychiatry. 2010 May.

Abstract

Objective: Inflammatory processes may play a role in the pathophysiology of schizophrenia. The aim of this study was to determine the efficacy of adjuvant treatment with aspirin (acetylsalicylic acid) in schizophrenia spectrum disorders.

Method: This randomized, double-blind, placebo-controlled study was conducted between May 2004 and August 2007. Seventy antipsychotic-treated inpatients and outpatients from 10 psychiatric hospitals in The Netherlands with a DSM-IV-diagnosed schizophrenia spectrum disorder were included. Patients were randomized to adjuvant treatment with aspirin 1000 mg/d or placebo. During a 3-month follow-up, psychopathology was assessed with the Positive and Negative Syndrome Scale (PANSS). Other assessments included cognitive tests and immune function. The primary efficacy outcome was the change in total PANSS score. Secondary outcomes were changes in the PANSS subscales and cognitive test results.

Results: Mixed-effect models showed a 4.86-point (95% CI, 0.91 to 8.80) and 1.57-point (95% CI, 0.06 to 3.07) larger decrease in the aspirin group compared to the placebo group on the total and positive PANSS score, respectively. Similar but not statistically significant results were observed for the other PANSS subscale scores. Treatment efficacy on total PANSS score was substantially larger in patients with the more altered immune function (P = .018). Aspirin did not significantly affect cognitive function. No substantial side effects were recorded.

Conclusion: Aspirin given as adjuvant therapy to regular antipsychotic treatment reduces the symptoms of schizophrenia spectrum disorders. The reduction is more pronounced in those with the more altered immune function. Inflammation may constitute a potential new target for antipsychotic drug development.

Trial registration: controlled-trials.com Identifier: ISRCTN27745631.

PubMed Disclaimer

Comment in

Adding aspirin to antipsychotics reduces psychopathology in adults with schizophrenia spectrum disorders.
Mondelli V, Pariante CM. Mondelli V, et al. Evid Based Ment Health. 2010 Nov;13(4):122. doi: 10.1136/ebmh.13.4.122. Evid Based Ment Health. 2010. PMID: 21036984 No abstract available.

Cited by

A myelin gene causative of a catatonia-depression syndrome upon aging.
Hagemeyer N, Goebbels S, Papiol S, Kästner A, Hofer S, Begemann M, Gerwig UC, Boretius S, Wieser GL, Ronnenberg A, Gurvich A, Heckers SH, Frahm J, Nave KA, Ehrenreich H. Hagemeyer N, et al. EMBO Mol Med. 2012 Jun;4(6):528-39. doi: 10.1002/emmm.201200230. Epub 2012 Apr 4. EMBO Mol Med. 2012. PMID: 22473874 Free PMC article.
Associations between C-reactive protein levels and cognition during the first 6 months after acute psychosis.
Fathian F, Løberg EM, Gjestad R, Steen VM, Kroken RA, Jørgensen HA, Johnsen E. Fathian F, et al. Acta Neuropsychiatr. 2019 Feb;31(1):36-45. doi: 10.1017/neu.2018.25. Epub 2018 Nov 5. Acta Neuropsychiatr. 2019. PMID: 30394240 Free PMC article. Clinical Trial.
Immunological Biomarkers as Predictors of Treatment Response in Psychotic Disorders.
Orbe EB, Benros ME. Orbe EB, et al. J Pers Med. 2023 Sep 15;13(9):1382. doi: 10.3390/jpm13091382. J Pers Med. 2023. PMID: 37763150 Free PMC article. Review.
Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin.
Berk M, Mohebbi M, Dean OM, Cotton SM, Chanen AM, Dodd S, Ratheesh A, Amminger GP, Phelan M, Weller A, Mackinnon A, Giorlando F, Baird S, Incerti L, Brodie RE, Ferguson NO, Rice S, Schäfer MR, Mullen E, Hetrick S, Kerr M, Harrigan SM, Quinn AL, Mazza C, McGorry P, Davey CG. Berk M, et al. BMC Med. 2020 Jan 17;18(1):16. doi: 10.1186/s12916-019-1475-6. BMC Med. 2020. PMID: 31948461 Free PMC article. Clinical Trial.
Commentary: Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders.
Westwell-Roper C, Stewart SE. Westwell-Roper C, et al. Front Psychiatry. 2020 Apr 22;11:264. doi: 10.3389/fpsyt.2020.00264. eCollection 2020. Front Psychiatry. 2020. PMID: 32425818 Free PMC article. No abstract available.

Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial - PubMed (original) (raw)